$430,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases Issues related to the Inflation Reduction Act's prescription drug provisions Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance Tax issues related to research and development"
You can find more data on corporate lobbying on Quiver Quantitative.
SRPT Hedge Fund Activity
We have seen 211 institutional investors add shares of SRPT stock to their portfolio, and 223 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 8,562,435 shares (-94.5%) from their portfolio in Q2 2025, for an estimated $146,417,638
- D. E. SHAW & CO., INC. added 4,474,232 shares (+101548.6%) to their portfolio in Q2 2025, for an estimated $76,509,367
- JANUS HENDERSON GROUP PLC removed 3,325,968 shares (-98.8%) from their portfolio in Q2 2025, for an estimated $56,874,052
- AVORO CAPITAL ADVISORS LLC removed 2,674,835 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $45,739,678
- FARALLON CAPITAL MANAGEMENT LLC removed 2,341,424 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $40,038,350
- BLACKROCK, INC. added 2,208,354 shares (+22.3%) to their portfolio in Q2 2025, for an estimated $37,762,853
- EXOME ASSET MANAGEMENT LLC added 2,000,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $34,200,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SRPT Analyst Ratings
Wall Street analysts have issued reports on $SRPT in the last several months. We have seen 8 firms issue buy ratings on the stock, and 4 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 09/22/2025
- Guggenheim issued a "Buy" rating on 09/15/2025
- B of A Securities issued a "Underperform" rating on 08/21/2025
- Wells Fargo issued a "Overweight" rating on 08/07/2025
- Oppenheimer issued a "Outperform" rating on 07/29/2025
- Needham issued a "Underperform" rating on 07/29/2025
- Jefferies issued a "Buy" rating on 07/24/2025
To track analyst ratings and price targets for SRPT, check out Quiver Quantitative's $SRPT forecast page.
SRPT Price Targets
Multiple analysts have issued price targets for $SRPT recently. We have seen 26 analysts offer price targets for $SRPT in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Kostas Biliouris from BMO Capital set a target price of $50.0 on 09/22/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $22.0 on 09/15/2025
- Joseph Schwartz from Leerink Partners set a target price of $15.0 on 09/09/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $5.0 on 08/25/2025
- Tazeen Ahmad from B of A Securities set a target price of $16.0 on 08/21/2025
- David Hoang from Deutsche Bank set a target price of $12.0 on 08/15/2025
- Yanan Zhu from Wells Fargo set a target price of $50.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
